Moderate Evidence
Research Overview
Sulanemadlin Research for TP53 Wild-Type Cancers
An evidence-based overview of research examining Sulanemadlin in the context of tp53 wild-type cancers. This page synthesizes findings from peer-reviewed literature.
Research Summary
Sulanemadlin is being developed for TP53 wild-type solid tumors and lymphomas. Phase 1/2 data showed 59% disease control rate with notable responses in peripheral T-cell lymphoma. Requires molecular confirmation of TP53wt status for patient selection.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Sulanemadlin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.